Clinical Trials
53 trialsNCT07621497 2026-06-02
FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07617246 2026-06-01
The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07618910 2026-06-01
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
Tang-Du Hospital
Phase 2 Not yet recruiting
NCT05099848 2026-05-22
A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT04908111 2026-04-06
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Phase 1/2 Suspended
NCT04727307 2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2 Recruiting
NCT06526338 2025-09-30
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
University of Louisville
Phase 2 Recruiting
NCT05229588 2025-08-15
Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations
HonorHealth Research Institute
Phase 2 Completed
NCT06356688 2025-08-08
A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT04778839 2025-08-06
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
Phase 1 Recruiting
NCT06205849 2025-07-25
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
University of California, San Diego
Phase 1 Recruiting
NCT03350126 2025-07-23
NIPICOL
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Active not recruiting
NCT06199895 2025-06-03
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
Tongji Hospital
Phase 2 Recruiting
NCT05870800 2025-05-25
NICER
Baylor College of Medicine
Phase 2 Recruiting
NCT05342194 2025-04-23
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Recruiting
NCT04048278 2025-03-03
Lidocaine Infusion in Pancreatic Cancer
University of Illinois at Chicago
Phase EARLY_PHASE1 Recruiting
NCT04863430 2025-02-21
Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
Peking University
Phase 2 Withdrawn
NCT06760520 2025-01-08
Short-course Radiotherapy Followed by CAPOX and Ivonescimab for Locally Advanced Rectal Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Not yet recruiting
NCT06710561 2024-12-03
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Injectable SPN01 in Phase I.
Beijing SonoPhotoNano Medical Technology Co., Ltd.
Phase 1 Not yet recruiting
NCT06641453 2024-10-16
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
Chinese PLA General Hospital
Phase 1/2 Not yet recruiting
NCT06599775 2024-09-19
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06486545 2024-08-26
Liposomal Irinotecan Combination Regimen for Second-line Treatment of Advanced Gastric Cancer
Hunan Cancer Hospital
Phase NA Not yet recruiting
NCT06508229 2024-07-18
Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC
Harbin Medical University
Phase 2 Not yet recruiting
NCT06415669 2024-05-29
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT04682847 2024-01-31
Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Unknown
NCT05996484 2023-08-21
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Nanfang Hospital, Southern Medical University
Phase 2 Not yet recruiting
NCT05250791 2023-06-09
FLICOR
Imperial College London
Phase NA Unknown
NCT04454905 2023-04-19
Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
Sun Yat-sen University
Phase 2 Unknown
NCT05742750 2023-02-24
A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT05720598 2023-02-09
POLA
Medical University of Lublin
Phase NA Unknown
NCT05280444 2022-12-29
Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma
Zhongda Hospital
Phase 2/3 Unknown
NCT04295330 2022-08-26
Efficacy of Intravenous Lidocaine on Postoperative Pain and Recovery in Patients Undergoing Hepatectomy
West China Hospital
Phase NA Completed
NCT05369650 2022-05-11
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
West China Hospital
Phase NA Unknown
NCT05160740 2022-02-04
ICGMFITinPLC
Zhujiang Hospital
Phase NA Unknown
NCT04615806 2022-01-25
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
Fujian Medical University Union Hospital
Phase NA Unknown
NCT04506138 2021-12-14
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
Phase 1/2 Unknown
NCT05053386 2021-09-22
Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma
Zhejiang Cancer Hospital
Phase NA Unknown
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT04225364 2021-02-02
Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma
Guangzhou Institute of Respiratory Disease
Phase 2 Completed
NCT03989310 2020-12-23
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT04625894 2020-11-12
The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer
Fudan University
Phase 1 Unknown
NCT04581876 2020-10-09
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer
Fudan University
Phase 2 Unknown
NCT03946917 2020-05-12
JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Unknown
NCT04345783 2020-04-14
Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer
Beijing Friendship Hospital
Phase 2 Unknown
NCT03192735 2020-02-05
Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT04004234 2019-07-09
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT01967875 2019-05-30
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
China Medical University, China
Phase 2 Terminated
NCT02584400 2019-03-08
HX4 SD
Maastricht Radiation Oncology
Phase 2 Terminated
NCT01681446 2018-06-01
Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression
Fudan University
Phase 3 Unknown
NCT02382237 2017-08-21
PETANC
Institut du Cancer de Montpellier - Val d'Aurelle
Phase NA Completed